Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
7.150
+0.410 (+6.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals Inc Cl A
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
August 18, 2024
Merging with a former rival will bolster its capabilities.
Via
The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
August 17, 2024
We'll know a little more about the biotech's prospects in a year and a half.
Via
The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
August 14, 2024
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...
Via
Talk Markets
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
August 14, 2024
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
August 08, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
August 05, 2024
Company to host public L(earnings) call on August 8th at 5:00 pm ET / 3:00 pm MT
From
Recursion Pharmaceuticals
Via
GlobeNewswire
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
August 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
August 13, 2024
Efficiency in core processes is set to increase substantially due to AI.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
August 12, 2024
From
Halper Sadeh LLC
Via
GlobeNewswire
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
August 12, 2024
There isn't much to suggest these businesses are actually vulnerable.
Via
The Motley Fool
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
August 11, 2024
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
August 08, 2024
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024
August 08, 2024
RXRX stock results show that Recursion Pharmaceuticals met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
August 08, 2024
From
Halper Sadeh LLC
Via
Business Wire
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
August 08, 2024
Operational complementarities expected to yield annual synergies of approximately $100 million
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Is Recursion Pharmaceuticals a Millionaire-Maker?
August 06, 2024
It's likely to experience a lot of growth.
Via
The Motley Fool
99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks
July 31, 2024
Artificial intelligence (AI) colossus Nvidia has stakes in five publicly traded companies -- four of which account for almost every cent of its AI-driven portfolio.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.
Via
Talk Markets
Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
July 27, 2024
There's a lot to like about the company using automation and artificial intelligence to improve the new drug-discovery process.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
25 Best Artificial Intelligence Stocks to Buy Right Now
July 25, 2024
Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
These 7 AI Stocks Were Major Movers On Monday/Tuesday - Here's Why
July 24, 2024
This article identifies the
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Millionaire-Maker Artificial Intelligence (AI) Stocks
July 18, 2024
For the next stage of the AI era, companies with purposeful, practical, and highly targeted solutions stand to benefit the most.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
Is Recursion Pharmaceuticals Stock a Buy?
July 14, 2024
The company is ambitious and exploring exciting areas, but it's still early in the game.
Via
The Motley Fool
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
July 13, 2024
This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump.
Via
The Motley Fool
3 Healthcare Stocks Injecting AI for Big Gains
July 13, 2024
Investors should keep a close eye on these AI healthcare stocks as they revolutionize the future of drug development and patient care.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
July 12, 2024
Via
Benzinga
These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street
July 12, 2024
Are the analysts right about these Nvidia-backed AI stocks?
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.